Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (C-CSF) in patients with secondary and therapy-related acute myelogenous leukemia

Leukemia

Volumn 11, Issue 1, 1997, Pages 16-21

  Gardin, C ^a   Chaibi, P ^b   De Revel, T ^c   Rousselot, P ^b   Turlure, P ^a   Miclea J M ^b   Nedellec G ^c   Dombret, H ^b  

^a BEAUJON HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c University of Paris Descartes   (France)

Author keywords

G CSF; Idarubicin; PBSC transplantation; Secondary AML; Therapy related AML

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOGENETICS; DISEASE COURSE; ENTEROCOLITIS; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; MYELODYSPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; STROKE; TOXICITY; TREATMENT FAILURE;

EID: 0031047667     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400536     Document Type: Article

References (13)

1. Mertelsmann R, Tzvi Thaler H, To L. Morphological classification, response to therapy, and survival in 263 adult patients with acute non-lymphoblastic leukemia. Blood 1980; 56: 773-781.
2. Keating MJ, McCredie KB, Benjamin RS, Bodey GP, Zander A, Smith TL, Freireich EJ. Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP). Blood 1981; 58: 584-591.
3. Preisler HD, Raza A, Barcos M, Azarnia N, Larson R, Walker I, Browman M, Grunwald H, D'Arrigo P, Doeblin T, Bloom M, Stein A, Logue G, Goldberg J, Kirshner J, Gottlieb A, Bennett J. Highdose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup study. J Clin Oncol 1987; 5: 75-82.
4. Gajewski JL, Ho WG, Nimer SD, Hirji KF, Gekelman L, Jacobs AD, Champlin RI. Efficacy of intensive chemotherapy for acute myelogenous leukaemia associated with a preleukaemic syndrome. J Clin Oncol 1989; 7: 1637-1645.
5. Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F. Prognostic factors in adult de nova myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 1991; 77: 497-501.
6. Kantarjian HM, Estey EH, Keating MJ. Treatment of therapy-related leukemia and myelodysplastic syndrome. In: Bloomfield CD, Herzig GP (eds.) Advanced in the Management of Adult Acute Leukemia. WB Saunders Co: Philadelphia, 1993, pp. 81-107.
7. Cheson BD, Jasperse DM, Simon R. A critical appraisal of lowdose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 1986; 4: 1857-1864.
8. Bolwell BJ, Cassileth PA, Gale RP. Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review. Leukemia 1987; 1: 575-579.
9. Cheson BD. Chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Semin Oncol 1992; 19: 85-94.
10. Saba HI, Ballester OF, Balducci L. Hemopoietic growth factors in myelodysplasia. Hematol Rev 1992; 5: 207-221.
11. Hirst WJR, Mufti GJ. Clinical annotation: management of myelodysplastic syndromes. Br J Haematol 1993; 84: 191-196.
12. De Witte T, Zwaan F, Hermans J, Vernant J, Kolb H, Vossen J, Lonnqvist B, Beelen D, Ferrant A, Gmür J, Liu Yin J, Troussard X, Cahn J, Van Lint M, Gratwohl A. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group. Br J Haematol 1990; 74: 151-155.
13. Runde V, de Witte T, Aul C, Gratwohl A, Niederwieser D, van Biezen A, Hermans J, Vernant J, Kolb H, Vossen J, Lönqvist B, Beelen D, Ferrant A, Arnold R, Cahn J, van Lint M, Verdonk L, Apperley J. Myelodysplastic syndromes (MDS) or leukemia following MDS (sAML) treated with allogenic bone marrow transplantation (BMT): a survey of the working party on chronic leukemia of the EBMT. Ann Hematol 1995; 70 (Suppl. II): A138.